Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: A retrospective multicenter analysis

Journal of Infection and Chemotherapy

Volumn 18, Issue 6, 2012, Pages 883-890

  Yanagimoto, Shintaro ^a   Yotsuyanagi, Hiroshi ^a   Kikuchi, Yoshimi ^b   Tsukada, Kunihisa ^b   Kato, Michio ^c   Takamatsu, Junki ^d   Hige, Shuhei ^e   Chayama, Kazuaki ^f   Moriya, Kyoji ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Acquired immunodeficiency syndrome; Chronic liver disease; Genotype; HBV DNA

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; SERUM ALBUMIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHRONIC LIVER DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEXUAL TRANSMISSION; THROMBOCYTE COUNT; VIRUS GENOME; VIRUS TRANSMISSION; CHI SQUARE DISTRIBUTION; MULTICENTER STUDY; VIROLOGY;

ADULT; CHI-SQUARE DISTRIBUTION; COINFECTION; FEMALE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; JAPAN; MALE; RETROSPECTIVE STUDIES;

EID: 84880428923     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0433-4     Document Type: Article

References (35)

1. Ministry of Health, Labour and Welfare of Japan (ed). Annual Health, Labour and Welfare Report 2010-2011, Tokyo, Japan, 2011
2. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-41. (Pubitemid 44232373)
3. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90-7. (Pubitemid 38328170)
4. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis. 2012;25:10-6.
5. Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10:133-42.
6. Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185-95.
7. Koike K, Kikuchi Y, Kato M, Takamatsu J, Shintani Y, Tsutsumi T, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res. 2008;38:310-4. (Pubitemid 351193960)
8. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat. 2010;17:879-86.
9. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-9. (Pubitemid 43053865)
10. Sherman KE, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. Hepatology. 2007;45:1566-77. (Pubitemid 46918341)
11. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005;19(suppl 3):S41-S416.
12. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805. (Pubitemid 40693195)
13. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-6. (Pubitemid 35472132)
14. Mendes-Correa M, Nunez M. Management of HIV and hepatitis virus coinfection. Expert Opin Pharmacother. 2010;11:2497-516.
15. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032-5. (Pubitemid 29203534)
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-2.
17. Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14:176-82.
18. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses. 2007;23:525-31. (Pubitemid 46700885)
19. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80. (Pubitemid 30038386)
20. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902. (Pubitemid 32042753)
21. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990;263:1218-22. (Pubitemid 20069919)
22. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods. 1999;80:97-112. (Pubitemid 29248907)
23. Usuda S, Okamoto H, Tanaka T, Kidd-Ljunggren K, Holland PV, Miyakawa Y, et al. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J Virol Methods. 2000;87:81-9. (Pubitemid 30345678)
24. Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS. 2011;25:1013-4.
25. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology. 2003;46:329-38. (Pubitemid 38037030)
26. Shibayama T, Masuda G, Ajisawa A, Hiruma K, Tsuda F, Nishizawa T, et al. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. J Med Virol. 2005;76:24-32. (Pubitemid 40446451)
27. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 2001;34:590-4. (Pubitemid 32786652)
28. Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol. 2009;47:1476-83.
29. Koibuchi T, Hitani A, Nakamura T, Nojiri N, Nakajima K, Jyuji T, et al. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol. 2001;64:435-40. (Pubitemid 32613729)
30. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS. 2011;25:1051-6.
31. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int. 2012;32:656-64.
32. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105-17. (Pubitemid 36055344)
33. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology. 2003;46:164-70. (Pubitemid 36928646)
34. Hiraoka A, Michitaka K, Kumagi T, Kurose K, Uehara T, Hirooka M, et al. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma. Oncol Rep. 2005;13:1159-63.
35. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA. 2001;98:12671-6. (Pubitemid 33020004)